Pulmocide Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pulmocide.com
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 123
- Registration Number
- NCT05238116
- Locations
- 🇫🇷
Clinical Research Site 097, Paris, France
🇫🇷Clinical Research Site 059, Strasbourg, France
🇩🇪Clinical Research Site 071, Würzburg, Bavaria, Germany
A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
- Conditions
- Pulmonary Aspergillosis
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 102
- Registration Number
- NCT05037851
- Locations
- 🇺🇸
Clinical Research Site 2, Houston, Texas, United States
🇺🇸Clinical Research Site 3, Houston, Texas, United States
🇺🇸Research Site, Saint Louis, Missouri, United States
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
- Conditions
- Lung Transplant InfectionAspergillosis
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03905447
- Locations
- 🇬🇧
Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
🇬🇧Wythenshawe Hospital, Manchester, United Kingdom
🇬🇧Harefield Hospital, Harefield, Uxbridge, United Kingdom
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 4
- Registration Number
- NCT03870841
- Locations
- 🇬🇧
Northwest Lung Research Centre, Manchester, United Kingdom
🇬🇧Royal Brompton Hospital, London, United Kingdom
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
- Conditions
- AsthmaRespiratory AspergillosisCOPDBronchiectasisRespiratory Candidiasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT03745196
- Locations
- 🇬🇧
Glenfield Hospital, Leicester, United Kingdom
🇬🇧Northwest Lung Research Centre, Manchester, United Kingdom
🇬🇧Royal Brompton Hospital, London, United Kingdom
Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 5
- Registration Number
- NCT03715023
- Locations
- 🇬🇧
Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo/vehicle
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT03382431
- Locations
- 🇬🇧
hVIVO Services Ltd, London, United Kingdom
A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Drug: PC786 - Repeat dosesDrug: PC786 - Single dosesDrug: Placebo - Repeat dosesDrug: Placebo - Single doses
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT03236233
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
- Conditions
- Aspergillosis
- Interventions
- Drug: PC945 - repeat dosesDrug: PC945 - single dosesDrug: Placebo - single dosesDrug: Placebo - repeat doses
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT02715570
- Locations
- 🇬🇧
Parexel EPCU, Harrow, Middlesex, United Kingdom